scholarly journals Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis

2020 ◽  
Vol 4 (6) ◽  
pp. s104
Author(s):  
Michael Cork ◽  
Diamant Thaçi ◽  
Lawrence Eichenfield ◽  
Peter Arkwright ◽  
Zhen Chen ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Safety And Efficacy

Abstract not available.

Treatment of Severe Atopic Dermatitis Patients with Cyclosporin A(CyA): the Long-Term Safety and Efficacy.

1999 ◽  
Vol 61 (3) ◽  
pp. 271-278
Author(s):  
Yumiko KUBOTA ◽  
Shuhei IMAYAMA ◽  
Hiroko MIYAHARA ◽  
Tomoko TANAHASHI ◽  
Yoko UEMURA ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Cyclosporin A ◽  
Severe Atopic Dermatitis ◽  
Safety And Efficacy

scholarly journals Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

2017 ◽  
Vol 139 (2) ◽  
pp. AB381 ◽  
Author(s):  
Mette Deleuran ◽  
Diamant Thaçi ◽  
Lisa A. Beck ◽  
Seth Forman ◽  
Weily Soong ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Safety And Efficacy

scholarly journals Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

2019 ◽  
Vol 47 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Hidemi Nakagawa ◽  
Osamu Nemoto ◽  
Atsuyuki Igarashi ◽  
Hidehisa Saeki ◽  
Ryusei Murata ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Adult Patients ◽  
Janus Kinase Inhibitor ◽  
Safety And Efficacy
Sign in / Sign up

Export Citation Format

Share Document